JP2014500873A5 - - Google Patents

Download PDF

Info

Publication number
JP2014500873A5
JP2014500873A5 JP2013538984A JP2013538984A JP2014500873A5 JP 2014500873 A5 JP2014500873 A5 JP 2014500873A5 JP 2013538984 A JP2013538984 A JP 2013538984A JP 2013538984 A JP2013538984 A JP 2013538984A JP 2014500873 A5 JP2014500873 A5 JP 2014500873A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
fusion protein
fgfr1
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538984A
Other languages
English (en)
Japanese (ja)
Other versions
JP6178240B2 (ja
JP2014500873A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/060661 external-priority patent/WO2012068030A1/en
Publication of JP2014500873A publication Critical patent/JP2014500873A/ja
Publication of JP2014500873A5 publication Critical patent/JP2014500873A5/ja
Application granted granted Critical
Publication of JP6178240B2 publication Critical patent/JP6178240B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538984A 2010-11-15 2011-11-14 高用量の可溶性fgfr1融合タンパク質を用いるがんの治療 Expired - Fee Related JP6178240B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41394010P 2010-11-15 2010-11-15
US61/413,940 2010-11-15
US42146210P 2010-12-09 2010-12-09
US61/421,462 2010-12-09
PCT/US2011/060661 WO2012068030A1 (en) 2010-11-15 2011-11-14 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016175357A Division JP2017019843A (ja) 2010-11-15 2016-09-08 高用量の可溶性fgfr1融合タンパク質を用いるがんの治療

Publications (3)

Publication Number Publication Date
JP2014500873A JP2014500873A (ja) 2014-01-16
JP2014500873A5 true JP2014500873A5 (cg-RX-API-DMAC7.html) 2014-12-25
JP6178240B2 JP6178240B2 (ja) 2017-08-09

Family

ID=44993965

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013538984A Expired - Fee Related JP6178240B2 (ja) 2010-11-15 2011-11-14 高用量の可溶性fgfr1融合タンパク質を用いるがんの治療
JP2013538985A Expired - Fee Related JP5945277B2 (ja) 2010-11-15 2011-11-14 Fgfr1細胞外ドメイン併用療法
JP2016106022A Pending JP2016196475A (ja) 2010-11-15 2016-05-27 Fgfr1細胞外ドメイン併用療法
JP2016175357A Pending JP2017019843A (ja) 2010-11-15 2016-09-08 高用量の可溶性fgfr1融合タンパク質を用いるがんの治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013538985A Expired - Fee Related JP5945277B2 (ja) 2010-11-15 2011-11-14 Fgfr1細胞外ドメイン併用療法
JP2016106022A Pending JP2016196475A (ja) 2010-11-15 2016-05-27 Fgfr1細胞外ドメイン併用療法
JP2016175357A Pending JP2017019843A (ja) 2010-11-15 2016-09-08 高用量の可溶性fgfr1融合タンパク質を用いるがんの治療

Country Status (14)

Country Link
EP (2) EP2640377B1 (cg-RX-API-DMAC7.html)
JP (4) JP6178240B2 (cg-RX-API-DMAC7.html)
KR (3) KR101910779B1 (cg-RX-API-DMAC7.html)
CN (2) CN107050426A (cg-RX-API-DMAC7.html)
AU (2) AU2011329125B2 (cg-RX-API-DMAC7.html)
BR (2) BR112013012040A2 (cg-RX-API-DMAC7.html)
CA (2) CA2817537A1 (cg-RX-API-DMAC7.html)
EA (2) EA025828B1 (cg-RX-API-DMAC7.html)
IL (2) IL226248A0 (cg-RX-API-DMAC7.html)
MX (2) MX349293B (cg-RX-API-DMAC7.html)
NZ (4) NZ610487A (cg-RX-API-DMAC7.html)
SG (2) SG190248A1 (cg-RX-API-DMAC7.html)
WO (2) WO2012068032A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201303501B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
WO2013074492A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. Methods of treating cancer
CA2908391A1 (en) * 2013-05-01 2014-11-06 Five Prime Therapeutics, Inc. Methods of treating cancer
WO2014190147A2 (en) * 2013-05-23 2014-11-27 Five Prime Therapeutics, Inc. Methods of treating cancer
EA034376B1 (ru) * 2013-07-05 2020-01-31 Интегра Медикал Инк. Композиции для оздоровления полости рта
WO2015066452A2 (en) * 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating pediatric cancers
MX394623B (es) 2016-02-04 2025-03-24 Ads Therapeutics Llc Tecnología de sinergismo anticuerpo-fármaco para el tratamiento de enfermedades.

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5288855A (en) 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ATE243253T1 (de) 1990-07-06 2003-07-15 Rhone Poulenc Rorer Internat H Rezeptoren der wachstumsfaktoren aus fibroblasten
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5229501A (en) 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
WO2000046380A2 (en) 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
PT1292335E (pt) 2000-06-23 2007-08-13 Bayer Schering Pharma Ag Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii)
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
KR100976076B1 (ko) 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
WO2006081430A2 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
ZA200903134B (en) * 2006-11-28 2010-08-25 Centelion Modified soluble FGF receptor FC fusions with improved biological activity
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗-vegf抗體
PT2498799T (pt) * 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2

Similar Documents

Publication Publication Date Title
Bouattour et al. Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma
US12459974B2 (en) Bicyclic peptide ligands specific for Nectin-4
Lieu et al. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis
Doycheva et al. Systemic therapy for advanced hepatocellular carcinoma: an update of a rapidly evolving field
JP2024010052A (ja) 組織石灰化の治療方法
JP2014526441A5 (cg-RX-API-DMAC7.html)
MX2013005294A (es) Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
AU2015255752B2 (en) Methods and compositions for treating Cystic Fibrosis
JP2018140999A (ja) アデノウイルスを用いた治療方法
Seystahl et al. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Jitawatanarat et al. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib
EA201390722A1 (ru) Лечение рака повышенными дозами растворимых белков слияния fgfr1
WO2007120690A2 (en) Combination histamine h1r and h4r antagonist therapy for treating pruritus
JP5433581B2 (ja) 非定型抗精神病薬の使用に関連した体重増加を遅延させるための製薬組成物
BRPI0812835B1 (pt) Combinações e produtos contendo um agente inibidor de vegf e do irinotecano.
JP2013543870A5 (cg-RX-API-DMAC7.html)
Li et al. Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model
EP2285416B1 (en) Conjugates for the treatment of mesothelioma
Korpanty et al. Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?
Lemieux et al. Targeting the fibroblast growth factor receptors for the treatment of cancer
Wang et al. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond
CN115427056A (zh) 使用actriib配体陷阱和菲卓替尼治疗贫血的方法
Ciccozzi et al. cAsɛ sruov
WO2012019192A2 (en) Cell-permeable molecules as growth factor receptor antagonists
JP2016509018A5 (cg-RX-API-DMAC7.html)